THERAPY DOSSIER · th-d52e1a2b21a2

miR-199a downregulation (anti-miR-199a)

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29351405 ↗2018Reported benefit

Acute downregulation of miR-199a attenuates sepsis-induced acute lung injury by targeting SIRT1.

MouseEndotoxin/LPSC57BL/6MaleAcute downregulation in the setting of sepsis-induced lung injury

Model: Sepsis-induced acute respiratory distress syndrome; lipopolysaccharide stimulation of alveolar macrophages and a sepsis-induced acute lung injury model

Downregulating miR-199a reduced alveolar macrophage inflammatory cytokines, improved lung histopathology and reduced apoptosis via upregulation of SIRT1, with the benefit lost when SIRT1 was inhibited.

Extraction: extract · Supplied extraction confidence: 0.62. Machine-extracted fields require source verification.

Loading the evidence…